Pfizer and Blackstone Life Sciences sign funding deal for obesity program
FROM THE WIRE · FINANCE.YAHOO.COM
Blackstone to provide Pfizer up to $1.5 billion through 2028 to support clinical program for GLP-1 receptor agonist NEW YORK & CAMBRIDGE, Mass., November 11, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Blackstone Life Sciences ("Blackstone") today announced a strategic…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishUp to $1.5 billion in funding reduces Pfizer's development risk in its obesity program.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Blackstone will provide Pfizer up to $1.5 billion of development costs through 2028.
- 02The funding supports berobenatide, a monthly GLP-1 receptor agonist being studied for obesity.
- 03Blackstone will receive milestone-based payments tied to regulatory approval and sales.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Pfizer Inc.29.45 USDMarket closedtoday +0.31%Positive Blackstone Inc.121.97 USDMarket closedtoday -0.46%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets